Sino Biopharmaceutical Ltd. has moved two internally developed assets closer to commercialization in China, with the Center for Drug Evaluation accepting NDAs for HER2 dual-epitope bispecific antibody-drug conjugate TQB-2102 and IL-4Rα monoclonal antibody TQH-2722.